The study expands on the known genetic subtypes, shows that they are correlated with clinical outcome, and paves the way for better subtype-driven patient management.
A multistage GWAS suggests inherited SNPs at four sites in the genome can contribute to the risk of developing myeloproliferative neoplasms.
Researchers have found that the order in which TET2 and JAK2 mutations are acquired may impact drug response and disease progression.
The 95-gene test is for detecting leukemia, myelodysplastic syndromes, and myeloproliferative disorders and can return results in less than one week.
Qiagen said this week that it has signed an agreement with Eli Lilly to develop a companion diagnostic for an early-stage compound that Lilly is developing to treat blood cancer.
By Turna Ray
Qiagen and Eli Lilly have partnered to develop and commercialize a molecular diagnostic that will help pick out best responders to a blood cancer drug that is in early development in Lilly's pipeline.
The Leukemia and Lymphoma Society grant will fund genome-wide analysis research.
The acquisition will also bolster Qiagen's personalized medicine play through the addition of Ipsogen's extensive portfolio of personalized diagnostics and prognostics in the area of blood cancer.
Pacific Biosciences is hosting a competition in which researchers are vying to win free sequencing for an organism with the most interesting genome.
An opinion piece appearing in Newsday likens familial DNA searches to stop-and-frisk policies.
The San people of Africa have drawn up a code of conduct for researchers, according to the Conversation.
In Nature this week: genotypes linked to hip osteoarthritis, and more.